Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Merck and Daiichi Sankyo voluntarily withdrew their U.S. application for accelerated approval of an experimental lung-cancer therapy. The withdrawal delays a potential commercial launch and introduces regulatory uncertainty for the companies' oncology pipeline, likely weighing on sentiment toward the program.